http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 08:06:50 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/BioCardia+receives+Japan+PMDA+support+for+CardiAMP+cell+therapy+submission/26561526.html <p>BioCardia Inc. (NASDAQ: BCDA) announced that Japan's Pharmaceutical and Medical Device Agency has provided a consultation record supporting the company's regulatory submission for approval of its CardiAMP cell therapy to treat ischemic heart failure with reduced ejection fraction.</p><p>The PMDA consultation record confirms alignment on remaining questions to address before and as part of the submission for regulatory approval. The agency noted that positive outcomes seen in the company's three completed clinical trials were credible. The therapy would target ischemic heart failure patients with elevated biomarkers of heart stress on stable guideline directed medical therapy.</p><p>PMDA estimates that 20,000 of the 300,000 http://www.streetinsider.com/Corporate+News/BioCardia+receives+Japan+PMDA+support+for+CardiAMP+cell+therapy+submission/26561526.html Thu, 28 May 2026 08:06:50 -0400 BCDA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+28/26561442.html si-local-file:///var/storage/secattach/20260528/26561442.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+28/26561442.html Thu, 28 May 2026 08:00:00 -0400 BCDA O.00180101 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+28/26561442.html si-local-file:///var/storage/secattach/20260528/26561442.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+28/26561442.html Thu, 28 May 2026 08:00:00 -0400 BCDA O.00180101 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Press+Releases/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html <p align="left">SUNNYVALE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported the Consultation Record from Japan’s Pharmaceutical and Medical Device Agency (PMDA) supports submission for regulatory approval of the CardiAMP® cell therapy for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF) based on the Company’s three completed clinical trials of this therapy in HFrEF.</p> <p>PMDA’s Consultation Record confirms alignment on remaining questions to address before, and as part of the submission, for regulatory approval http://www.streetinsider.com/Globe+Newswire/BioCardia+Announces+Japan+PMDA+Record+Of+Advice+Supports+Regulatory+Submission+For+Approval+Of+CardiAMP+Cell+Therapy+For+Ischemic+Heart+Failure/26561408.html Thu, 28 May 2026 08:00:00 -0400 A.05963196 A.28005717 BCDA O.00180101 O.05375760 O.20020231 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+19++Filed+by%3A+Altman+Peter/26537217.html si-local-file:///var/storage/secattach/20260521/26537217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+19++Filed+by%3A+Altman+Peter/26537217.html Thu, 21 May 2026 18:15:00 -0400 BCDA O.00180101 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+19++Filed+by%3A+Altman+Peter/26537217.html si-local-file:///var/storage/secattach/20260521/26537217.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+19++Filed+by%3A+Altman+Peter/26537217.html Thu, 21 May 2026 18:15:00 -0400 BCDA O.00180101 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+21/26531780.html si-local-file:///var/storage/secattach/20260521/26531780.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+21/26531780.html Thu, 21 May 2026 08:04:00 -0400 BCDA O.00180101 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+21/26531780.html si-local-file:///var/storage/secattach/20260521/26531780.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++BioCardia%2C+Inc.+++++++++++For%3A+May+21/26531780.html Thu, 21 May 2026 08:04:00 -0400 BCDA O.00180101 http://www.streetinsider.com/Corporate+News/BioCardia+reports+trial+shows+cell+therapy+improves+heart+symptoms/26531750.html <p>BioCardia Inc. (NASDAQ: BCDA) reported trial results showing its CardiAMP cell therapy improved exercise tolerance and reduced chest pain episodes in patients with chronic heart disease.</p><p>The CardiAMP Chronic Myocardial Ischemia trial results were presented at the EuroPCR conference in Paris by Dr. Amish Raval from the University of Wisconsin School of Medicine and Public Health.</p><p>The open-label study showed patients experienced an average increase of 179 seconds in exercise tolerance that persisted through two years of follow-up. Chest pain episodes decreased by an average of 82% at six months after treatment, according to the company.</p><p>The minimally invasive procedure uses a patient's http://www.streetinsider.com/Corporate+News/BioCardia+reports+trial+shows+cell+therapy+improves+heart+symptoms/26531750.html Thu, 21 May 2026 08:02:09 -0400 BCDA http://www.streetinsider.com/FDA/BioCardia+reports+trial+shows+cell+therapy+improves+heart+symptoms/26531750.html <p>BioCardia Inc. (NASDAQ: BCDA) reported trial results showing its CardiAMP cell therapy improved exercise tolerance and reduced chest pain episodes in patients with chronic heart disease.</p><p>The CardiAMP Chronic Myocardial Ischemia trial results were presented at the EuroPCR conference in Paris by Dr. Amish Raval from the University of Wisconsin School of Medicine and Public Health.</p><p>The open-label study showed patients experienced an average increase of 179 seconds in exercise tolerance that persisted through two years of follow-up. Chest pain episodes decreased by an average of 82% at six months after treatment, according to the company.</p><p>The minimally invasive procedure uses a patient's http://www.streetinsider.com/FDA/BioCardia+reports+trial+shows+cell+therapy+improves+heart+symptoms/26531750.html Thu, 21 May 2026 08:02:09 -0400 BCDA http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html <p><strong><em>– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development</em></strong></p> <p><strong><em>– Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options </em></strong></p> <p>SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html Thu, 21 May 2026 08:00:00 -0400 A.12763360 BCDA O.00180101 O.20319167 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html <p><strong><em>– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development</em></strong></p> <p><strong><em>– Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options </em></strong></p> <p>SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html Thu, 21 May 2026 08:00:00 -0400 A.12763360 BCDA O.00180101 O.20319167 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html <p><strong><em>– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development</em></strong></p> <p><strong><em>– Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options </em></strong></p> <p>SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html Thu, 21 May 2026 08:00:00 -0400 A.12763360 BCDA O.00180101 O.20319167 http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html <p><strong><em>– Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory angina and validate continued clinical development</em></strong></p> <p><strong><em>– Novel therapeutic approach targets a critically important unmet medical need for patients who have debilitated quality-of-life and have exhausted all available treatment options </em></strong></p> <p>SUNNYVALE, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the oral presentation of the results of the CardiAMP® Cell Therapy http://www.streetinsider.com/Press+Releases/BioCardia+Announces+CardiAMP+Chronic+Myocardial+Ischemia+Trial+Results+Presented+at+EuroPCR+Showed+Durable+Improvements+in+Exercise+Tolerance+with+Reduced+Angina+Frequency/26531714.html Thu, 21 May 2026 08:00:00 -0400 A.12763360 BCDA O.00180101 O.20319167